IZQVF News and Press, Indivior PLC

2023-04-29 07:56:06 ET Indivior PLC (INVVY) Q1 2023 Earnings Conference Call April 27, 2023 08:00 AM ET Company Participants Jason Thompson - Vice President of Investor Relations Mark Crossley - Chief Executive Officer Christian Heidbreder - Chief Scientific Offi...

2023-04-28 02:06:35 ET The following slide deck was published by Indivior PLC in conjunction with their 2023 Q1 earnings call. For further details see: Indivior PLC 2023 Q1 - Results - Earnings Call Presentation

2023-04-07 08:09:06 ET Summary Opioid treatment provider Indivior has seen a 20%+ price rise in 2023, but its latest financials are not supportive. The company swung into a loss for FY22 on the provision for litigation, which is a red flag, considering that these costs could mount...

The following slide deck was published by Indivior PLC in conjunction with their 2023 Q4 earnings call. For further details see: Indivior PLC 2023 Q4 - Results - Earnings Call Presentation

Indivior PLC (INVVY) Q4 2022 Earnings Conference Call February 16, 2023 08:00 ET Company Participants Jason Thompson - Vice President of Investor Relations Mark Crossley - Chief Executive Officer Christian Heidbreder - Chief Scientific Officer Ryan Preblick - Chief...

Addex Therapeutics ( NASDAQ: ADXN ) and Indivior ( OTCPK:INVVY ) ( OTCPK:IZQVF ) extended their collaboration on discovering and developing novel oral gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) drug candidates until March 31, 2023...

Indivior PLC (INVVY) Q2 2022 Earnings Conference Call July 28, 2022 08:00 AM ET Company Participants Mark Crossley - Chief Executive Officer Ryan Preblick - Chief Financial Officer Christian Heidbreder - Chief Scientific Officer Conference Call Participants...

The following slide deck was published by Indivior PLC in conjunction with their 2022 Q2 earnings call. For further details see: Indivior PLC 2022 Q2 - Results - Earnings Call Presentation

Indivior PLC ADR press release ( OTCPK:INVVY ): Q2 Non-GAAP EPS of $0.06. Revenue of $221M (+10.0% Y/Y). Outlook: Total FY 2022 expected NR range maintained at $840M to $900M (+10% vs. FY 2021 at the mid-point); Adjusted gross margin expected to be in the low- to mid-8...

The following slide deck was published by Indivior PLC in conjunction with this event. For further details see: Indivior (INVVY) Presents At Jefferies Healthcare Conference - Slideshow